Eliquis Regulatory Post Marketing Surveillance

NCT01885598 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3335

Last updated 2017-10-31

No results posted yet for this study

Summary

The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.

Conditions

  • NonValvular Atrial Fibrillation

Interventions

DRUG

Apixaban

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-10
Primary Completion
2017-09-29
Completion
2017-09-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885598 on ClinicalTrials.gov